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ABSTRACT
This study assessed whether an oral rehydration solution (ORS) in which glucose is replaced by L-
glutamine (L-glutamine ORS) is more effective than the standard glucose-based rehydration solution 
recommended by the World Health Organization (WHO-ORS) in reducing the stool volume and 
time to rehydrate in acute diarrhoea. In a double-blind, randomized controlled trial in a Mexican 
hospital, 147 dehydrated children, aged 1-60 month(s), were assigned either to the WHO-ORS (74 
children), or to the L-glutamine ORS (73 children) and followed until successful rehydration. There 
were no significant differences between the groups in stool output during the first four hours, time 
to successful rehydration, volume of ORS required for rehydration, urinary output, and vomiting. 
This was independent of rotavirus-associated infection. An L-glutamine-containing glucose-free ORS 
seems not to offer greater clinical benefit than the standard WHO-ORS in mildly-to-moderately-de-
hydrated children with acute non-cholera diarrhoea.
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INTRODUCTION
During the last three decades, the distribution and 
promotion of oral rehydration solutions (ORS) 
have helped save millions of lives and have been 
a model as a cost-effective public-health interven-
tion, yet the standard glucose-based solution re-
commended by the World Health Organization 
(WHO-ORS) does not significantly reduce the gross 
stool volume nor the duration of the diarrhoeal 
episode. Thus, there has been a great interest in de-
veloping alternative efficacious ORS capable of re-
ducing stool output and duration of illness, which 
could enhance their acceptance by users (1).
The amino acid L-glutamine is a theoretically-use-
ful component in ORS because of its ability to act 
as a co-transport substrate with sodium, which 
leads to an increased absorption of NaCl, and its 
widely-known property as a fuel source for rapid 
turnover cells, including intestinal epithelial cells, 
lymphocytes, fibroblasts, and reticulocytes (2). 
Findings of animal and human studies have demon-
strated that glutamine supplementation can 
ameliorate the intestinal damage and improve the 
gastrointestinal function and gut and systemic im-
mune function (3). In a perfused rat ileum model 
exposed to cholera toxin, a dramatic reduction of 
toxin-induced water and sodium secretion, when 
a glutamine-based solution is used, has been 
demonstrated (3). This evidence suggests that a 
glutamine-based ORS might be the ideal solution 
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to facilitate absorption of sodium and water and 
to improve healing from an enteric infection.
In two clinical trials among children with non-
cholera diarrhoea, no advantage of the glutamine-
based ORS, compared to the WHO-ORS, was found 
(1,4); however, the former solution contained both 
glucose and glutamine, and its osmolarity was 380 
mOsm/L (vs 311 mOsm/L in the WHO-ORS), which 
may explain the observed lack of benefit from the 
glutamine-ORS. Glutamine is an effective co-trans-
porter of sodium in diarrhoea but its superiority to 
glucose in terms of limiting stool volume has not 
been proved in these studies, probably due to the 
high osmolarity of the experimental solutions.
Because there is no published study testing the 
efficacy of an ORS in which glucose is replaced 
by L-glutamine, we were interested in testing 
whether this solution, with a relatively low os-
molarity, could be a more effective ORS by re-
ducing the faecal volume in children with acute 
diarrhoea. The main objective of this study was to 
assess if an L-glutamine-containing, glucose-free 
ORS, could reduce the stool output and the rehy-
dration time in mildly-to-moderately dehydrated 
children with acute diarrhoea compared to the 
standard glucose-based formulation recommend-
ed by the WHO. 
MATERIALS AND METHODS
Study design 
This is a double-blind, randomized controlled clini-
cal trial. Eligible children were randomly allocated to 
either of the two study arms: the L-glutamine-based 
solution or the glucose-based solution (WHO-ORS).
Eligibility criteria 
We included children aged 1-60 month(s) who had 
diarrhoea (defined as the passage of three or more 
loose or watery stools in the 24-hour period prior 
to enrollment) for not more than five days, with 
dehydration (with at least two of the diagnostic 
signs given by the WHO guidelines) and seen at the 
Oral Rehydration Service of the Hospital Infantil de 
México Federico Gómez during 1 September 2002–
1 December 2003. Eligible children were screened 
at the hospital by a paediatrician and included in 
the study if the responsible caregiver signed a writ-
ten informed consent to participate. A child was ex-
cluded if he or she had severe dehydration and/or 
hypovolemic shock, altered consciousness, dysen-
tery, severe malnutrition (5), or high stool output 
(defined as ≥10 mL/kg/hour). Children were elimi-
nated from the study when the caregiver asked for 
voluntary drop-out, or when the child had incom-
plete laboratory results.
Baseline assessment 
A thorough clinical history, which included data 
on family history, duration of diarrhoea, flu-
ids ingested prior to admission of patient, num-
ber of stools and vomits in the previous 24 hours, 
presence of fever (≥38.0 oC), and body-weight 
and height. On admission, all children were 
weighed using a scale with 50-g sensitivity (Tanita 
model 1580, Tokyo, Japan). A faecal sample was 
obtained for identification of rotavirus, Vibrio chole-
rae, and other common enteropathogens, such 
as Shigella spp., Salmonella spp., and Campylobacter 
jejuni, and to determine faecal-specific gravity. A 
blood sample was obtained to measure urea, crea-
tinine, glucose, sodium, potassium, and osmo-
lality. A urine sample was obtained to measure 
sodium, potassium, osmolality, and specific gra-
vity.
Interventions 
Both WHO-ORS and L-glutamine ORS were packed 
in identical bags, and their administration started 
on the day of enrollment. The WHO-ORS contained 
sodium  chloride−3.5  g/L,  dihydrated  trisodic  ci-
trate−2.9 g/L, potassium chloride−1.5 g/L, and an-
hydride glucose−20.0 g/L and had a total osmolari-
ty of 311 mOsm/L. The L-glutamine-based solution 
contained sodium chloride−3.5 g/L, dihydrated tri-
sodic citrate−2.9 g/L, potassium chloride−1.5 g/L, 
and L-glutamine−20.0 g/L and had a total osmolar-
ity of 284 mOsm/L. Both the solutions were iden-
tical in appearance and taste and were identified 
with a secret code (double-blinding). Additionally, 
both the solutions were assigned a unique serial 
number. The randomization list that linked serial 
numbers with the ORS group identity was kept at 
the Hospital’s Pharmacy until the end of enroll-
ment and follow-up. The study staff was blinded 
to the ORS assigned, while the child remained in 
the study. The assigned solution was given to the 
mother with instructions for administration to her 
child, along with standard messages on appropri-
ate feeding (6-8) according to the recommenda-
tions of WHO. Both the study groups received the 
oral solution at an initial amount of 100 mL/kg for 
four hours; this was given by the patient’s mother 
in fractionated doses every 30 minutes using cup 
and spoon. If vomiting occurred in excess of once 
per hour, oral administration was withheld for 20 
minutes; if there was no abdominal complication 
that contraindicated oral intake, the ORS was re-
introduced and increased at a dose of 0.5 mL per Gutierrez C et al. Glutamine-based oral rehydration solution
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kg/weight every five minutes. If the child did not 
vomit for 10 minutes, intake was progressively 
increased until reaching the initial dose. If the 
child continued vomiting, the patient underwent 
rehydration using a nasogastric tube at an amount 
of 25-30 mL per kg of weight per hour. If vomits 
persisted, despite the use of the nasogastric tube, 
the child was rehydrated by the intravenous (IV) 
route. 
Follow-up and outcome measurements
All patients were clinically evaluated every hour, 
and data were registered. Faeces, vomits, and urine 
were collected in plastic bags or graduated recipi-
ents and their volume quantified every hour. The 
main outcome measure was the time to achieve 
a successful rehydration, i.e. the span between 
the start of oral rehydration therapy (ORT) and 
the moment rehydration was achieved. Rehydra-
tion was defined as when (a) the child presented 
none or only one of the signs of dehydration, 
(b) the stool output was less than 10 mL/weight 
kg/hour, (c) the urinary-specific gravity was less 
than 1,030, and (d) body-weight was stable dur-
ing three consecutive hours. When this occurred, 
usual feeding was re-introduced, and the care-
giver was trained to continue treatment at home. 
Two definitions of failure to rehydrate were used. 
One was when the child presented a stool output 
of ≥10 mL/weight kg/hour during four consecu-
tive hours without improvement of the signs 
of hydration status and the other, when dehy-
dration signs worsened at any moment of treat-
ment. When the former definiton occurred, a 
rice starch powder solution was started at a dose 
of 25 mL/weight kg/hour until reduction in 
stool output, if no worsening of dehydration, 
was observed. If after another four hours, the 
stool volume did not decrease with the rice starch 
solution or if dehydration signs worsened, the 
child was rehydrated using the intravenous route. 
Osmotic diarrhoea was defined as when the faeces 
osmolality (Na faecal + K faecal × 2) was ≥100.
Ethics 
The trial received ethical clearance from the Ethics 
and Investigation Committee of the Hospital In-
fantil de México Federico Gómez in Mexico City. 
Implementation of all aspects of the project was in 
agreement with the International Ethical Guide-
lines for Research Involving Subjects, as stated 
in the latest version of the Helsinki Declaration. 
Informed and written consent was obtained from 
parents at the beginning of the study.
Statistics 
Statistical analyses were undertaken using the SPSS 
(version 10.0) statistical data management program 
package. All analyses were conducted on an inten-
tion-to-treat basis. The Mann-Whitney U test was 
used for determining the differences between me-
dians, chi-square test for the comparison of propor-
tions, and the Spearman’s correlation coefficient 
(Rs) in the assessment of the association between 
two dimensional scale values. The odds ratio (OR) 
and its 95% confidence interval (CI) were calculated 
in 2 by 2 contingency tables. The time-dependent 
cumulative probability of achieving a rehydration 
status was calculated using the Kaplan Meier analy-
sis and the comparison between curves, according 
to the type of ORS, was made with the Log rank 
test. The proportional hazard ratio (HR) and its 95% 
CI of the time to a successful rehydration with the 
L-glutamine ORS, with the WHO-ORS as the refer-
ence, were estimated with a Cox regression model. 
A minimum sample size of 124 patients was calcu-
lated as required to have a power of 80% to detect 
as a statistically significant (two-tailed p value at 
5%) difference between groups, in the stool output, 
of at least 30% (9). Considering the possibility of up 
to a 20% drop-out rate, 74 children were enrolled 
to be assigned to each of the two arms of the trial.
RESULTS
In total, 148 dehydrated children with diarrhoea 
were enrolled into the study. Seventy-four were 
randomly allocated to receive the WHO-ORS and 
73 the L-glutamine solution. Parents of one child 
in the L-glutamine ORS group decided to volun-
tarily drop-out from the study. Baseline charac-
teristics at study entry were comparable between 
both the groups, including rotavirus and bacte-
rial identification in faeces (p>0.05) (Table 1).
All children were successfully rehydrated with ORS 
and discharged alive from the Hospital. The cumu-
lative probability of being rehydrated at 4, 6, and 
10 hours in the WHO-ORS group was 26%, 64%, 
and 93% respectively, and in the L-glutamine-ORS 
group, these frequencies were 34%, 67%, and 97% 
respectively (Log-rank test, p=0.69). Only one pa-
tient from each group required 12 hours or more 
to be rehydrated. In the time to rehydrate analy-
sis, the hazard ratio of the effect of the glutamine-
based ORS, with the WHO-ORS as the reference, 
was calculated to be 1.06 (95% CI 0.76-1.46).
Six children (8%) in the WHO-ORS group and 
four children (5%) in the L-glutamine-ORS group 
showed failure to the original ORS, and this was 
changed to a rice-powder ORS (OR=0.66; 95% CI 
0.15-2.79; p=0.53; with the WHO-ORS as the refer-
ence group). One patient (1.3%) in the WHO-ORS 
group, failed treatment due to persistent vomit-
ing, was rehydrated with the WHO-ORS through 
nasogastric tube and subsequently returned to the 
oral route.Gutierrez C et al. Glutamine-based oral rehydration solution
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Table 1. Baseline characteristics of 147 enrolled children
Variable
WHO-ORS
(n=74)
L-glutamine ORS
(n=73)
p value
Median age (months) (minimum-maximum) 11 (1-39) 10 (2-34) 0.63*
Male gender, no. (%) 47 (63.5) 43 (58.9) 0.56†
Nutritional status, no. (%)
First-grade malnutrition
Second-grade malnutrition
41 (55.4)
13 (17.6)
37 (50.6)
9 (12.3)
0.16†
Percentage of dehydration‡, median (mini-
mum-maximum) 4.3 (1-10.8) 4.2 (2-10.2) 0.59*
Time (hours) with diarrhoea before enroll-
ment, median (minimum-maximum) 37 (5-120) 47 (10-120) 0.16*
Total number of stools 24 hours before 
   enrollment, median (minimum–maximum)  8 (1-27) 10 (2-30) 0.053*
Total number of vomits 24 hours before 
   enrollment, median (minimum-maximum)  6 (0-23) 6 (0-28) 0.96*
Fever ≥38.0, no. (%) 40 (56.8) 47 (62.3) 0.20†
Antibiotic use, no. (%)
Anti-diarrhoeic use, no. (%)
Use of hyperosmolar fluid, no. (%)
42 (56.8)
18 (24.3)
8 (10.8)
44 (60.3)
11 (15.0)
13 (17.8)
0.66†
0.16†
0.22†
Reporting rotavirus in faeces, no. (%)
   Salmonella group D
   Campylobacter jejuni
   Pseudomonas aureuginosa
   Shigella sonnei
35 (47.3)
1
0
1
0
27 (37.0)
1
2
1
1
0.20†
0.99†
0.15†
0.99†
0.31†
Serum sodium level, median (mEq/L) (mini-
mum-maximum)
Serum glucose level, median (mg/dL) (mini-
mum-maximum)
Urinary gravity, median (minimum-maximum)
140 (116-158)
92 (42-155)
1,028 (1,025-1,030)
138 (116-158)
90 (59-180)
1,027 (1,024-1,030)
0.24*
0.59*
0.41*
*Mann-Whitney U test; †χ2 test; ‡Weight at enrollment × 100/weight at end of rehydration
ORS=Oral rehydration solution; WHO=World Health Organization
The median time and volume of ORS required to 
correct dehydration and the stool, urine, and vomit 
output during the rehydration period were similar 
between both the groups (Table 2).
The median stool output (in mL/kg of body-
weight) during the first, second, third, and fourth 
hour since the start of ORS was 9.75, 8.45, 10.85, 
and 10.65 respectively in the WHO-ORS group and 
11.90, 13.70, 10.70, and 10.00 respectively in the 
L-glutamine ORS group. The differences between 
both the groups were not statistically significant. 
Another analysis stratifying children with and 
without rotavirus-associated infection showed 
that both the ORS treatment groups had similar 
volumes of stool output during these same time 
periods within each stratum (data not shown).
The subgroup analysis taking only children with 
rotavirus-associated infection (62 children) showed 
that the cumulative probability of being rehy-
drated at four, six, and eight hours in the WHO-
ORS group (35 children) was 23%, 69%, and 89% 
respectively, and in the L-glutamine-ORS group (27 
children), these frequencies were 41%, 67%, and 
100 % respectively (Log-rank test, p=0.22). The 
HR of the effect of the glutamine-based ORS, 
with the WHO-ORS as the reference, was cal-
culated to be 1.31 (95% CI 0.78-2.19). In addition, 
children with no rotavirus-associated infection 
(85 children), the cumulative probability of being 
rehydrated at 4, 6, and 8 hours, in the WHO-ORS 
group (39 children) was 28%, 59%, and 92% re-
spectively, and in the L-glutamine-ORS group (46 Gutierrez C et al. Glutamine-based oral rehydration solution
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Table 2. Main outcomes in children receiving two different oral rehydration solutions in the man-
agement of acute diarrhoea 
Variable
 WHO-ORS
(n=74)
L-glutamine 
ORS
(n=73)
 p value
Time (hours) required for rehydration, median 
  (minimum–maximum) 6 (3-12) 5 (3-15) 0.34*
Volume of ORS required for rehydration‡, median 
   (minimum–maximum) 24 (11-39) 24 (15-44) 0.72*
Stool output during the time to rehydration‡, 
  median (minimum–maximum) 11.35 (0-28.7) 11.8 (0.9-33.8) 0.80*
Urinary output during the time to rehydration‡, 
  median (minimum–maximum) 0.6 (0-4.9) 0.8 (0-6.6) 0.12*
Patients with vomits, no. (%); median of vomits 
No./hour (minimum–maximum)
17 (22.9)
0 (0-15)
23 (31.5)
0 (0-1)
0.24†
0.08*
Median of vomits/hour‡ (minimum–maximum) 0 (0-13.2) 0 (0-9.1) 0.17*
Diagnosis of osmotic diarrhoea¶, no. (%)  37 (52.0) 24 (40.0) 0.16†
*Mann-Whitney U test; †χ2 test; ‡(mL/kg/h); ¶Defined as when the osmolality of (Na faecal + K 
faecal × 2) faeces was ≥100
ORS=Oral rehydration solution; WHO=World Health Organization
children), these frequencies were 30%, 67%, and 
80% respectively (Log-rank test, p=0.86). The HR 
of the effect of the glutamine-based ORS, with the 
WHO-ORS as the reference, was calculated to be 
0.97 (95% CI 0.63-1.49).
No association between the volume of ingested ORS 
and the stool output was found in any of the two 
treatment groups (Rs=0.30 in the WHO-ORS group 
and Rs=0.53 in the L-glutamine solution group; 
p=0.20). The median levels of serum sodium and 
glucose, at the end of rehydration period, showed 
not to be significantly different between the groups 
(p=0.84 and p=0.25). No children developed hypo- 
or hypernatraemia or hypo- or hyperglycaemia at 
the end of the study. The median of serum creati-
nine, serum and urinary osmolality, and the pro-
portion of patients with osmotic diarrhoea, at the 
end of the study, were not significantly different 
between both the groups (p=0.55, 0.53, 0.64, and 
0.16 respectively).
DISCUSSION
There are few clinical trials in the literature that 
tested L-glutamine-containing oral rehydration so-
lutions. One trial was carried out in adults with 
cholera, and the other one in children with diar-
rhoea due to diverse aetiologic agents. The former 
study tested a solution with 50 mmol/L of glucose 
and 50 mmol/L of L-glutamine, with an osmolar-
ity of 300 mOsm/L, and showed a marked re-
duction in the stool output and in the dura-
tion of the diarrhoeal episode (1). In contrast, in 
the second study, the solution contained 90 mmol/
L of L-glutamine and 90 mmol/L of glucose, with 
an osmolarity of 380 mOsm/L, and showed no 
clinical benefit in children rehydrated with the L-
glutamine-added solution, probably due to the 
relatively high osmolarity of this ORS (4). 
Our study was designed to test the hypothesis that 
a water and electrolyte solution in which glucose, 
as co-transporter of these elements, is replaced by 
L-glutamine would lead to better clinical outcomes 
in the process of oral rehydration of children with 
acute non-cholera diarrhoea compared to the stan-
dard WHO-recommended glucose-containing ORS. 
The rationale for this hypothesis is based on two 
theoretical advantages of the former solution; first, 
the evidence from experimental models showing 
that supplemental glutamine can ameliorate the 
intestinal damage, enhance the gastrointestinal 
function, and reduce enteropathogens’ toxin-in-
duced water and sodium secretion in the gut and 
second, that through the elimination of glucose 
in our experimental ORS, the osmolarity of the 
solution is decreased from 300 to 380 mOsm/L (in 
the L-glutamine plus glucose-ORS) or from 311 
mOsm/L (in the glucose-containing WHO-ORS) 
to 284 mOsm/L (in the L-glutamine-containing, Gutierrez C et al. Glutamine-based oral rehydration solution
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glucose-free, ORS). To our knowledge, there is no 
published study testing the clinical efficacy of an 
L-glutamine-containing, glucose-free, ORS.
The results of our study showed a similar rate of 
successful rehydration, time to achieve it, and stool 
output during the first hours of rehydration ther-
apy,  among  children  receiving  the  experimental 
ORS compared to those under the standard WHO-
ORS.
There are several possible explanations for the lack 
of reduction of the stool volume and time to rehy-
drate in our children treated with the L-glutamine 
ORS. First, this amino acid might have a lesser ef-
fect on intestinal absorption of water and sodium 
in non-cholera diarrhoea compared to diarrhoea 
caused by V. cholerae, in which there is a relatively-
larger secretion of sodium and chloride ions in-
side the intestinal lumen (10). This latter situation 
would provide a larger amount of sodium that is 
co-transported with the L-glutamine with a conse-
quent major reduction in the stool output. These 
phenomena may not occur in diarrhoea second-
ary to other infectious agents, such as rotavirus 
and enteropathogenic Escherichia coli, as is the 
case with most of our study children. Second, it is 
widely known that rotavirus is the main cause of 
severe dehydrating diarrhoea, frequently associa-
ted with a high rate of stool output (11,12); thus, 
the inclusion of these patients in our study (42% 
of the total study sample) might have diluted a 
possible beneficial effect of the L-glutamine ORS 
in children with diarrhoea by other aetiologies. 
Yet, a stratified analysis of a subgroup of children 
with rotavirus-associated or rotavirus-free diar-
rhoea showed no differential clinical effect for the 
L-glutamine ORS. Third, it might be that a high 
intake of ORS could lead to a larger faecal volume 
during the rehydration period, as suggested by 
others (13); however, in the analysis of our own 
data, such association was not found.
Worth mentioning is that none of our patients 
developed hypoglycaemia (14), despite the fact 
that the experimental solution did not contain 
glucose. Ronan et al. reported transitory hyper-
glycaemia associated with dehydration-generated 
stress in patients with acute diarrhoea (15). This 
may explain why in our children blood glucose 
remained within the normal range at the end of 
the rehydration period.
In contrast to results of other similar studies, we 
included both male and female children to be 
able to generalize our results to the overall infant 
population. A potential problem with this strategy 
is the error in the measurement of the urine and 
stool volumes, as they can get mixed in female in-
fants. However, a special care was taken in separat-
ing and quantifying urine from stool outputs in 
our study. Moreover, we consider that the amount 
of urine in these infants could have been minimal 
due to the low rate of diuresis that dehydrated pa-
tients present during the rehydration period.
In the present research, we did not assess the total 
duration of diarrhoea and stool output after dis-
charge from the hospital, as outcome measures, 
because it is very difficult to reach a control of 
all the determinants of these events, such as the 
child’s feeding and oral fluids administered at 
home. This methodological issue may limit the 
external validity of our results
In conclusion, the glucose-free L-glutamine ORS 
seems not to offer an additional clinical bene-
fit over the standard glucose-based WHO-ORS, 
among dehydrated children aged less than five 
years with non-cholera acute diarrhoea. This lack 
of an additional advantage is independent of ro-
tavirus-associated infection. Because the cost of 
L-glutamine-based ORS is relatively high, its indi-
cation would be limited to certain circumstanc-
es, such as an alternative rehydration therapy in 
children in whom the glucose-based ORS is con-
traindicated due to transitory carbohydrate intol-
erance (16,17). Further studies are needed to test 
a possible clinical advantage of the L-glutamine 
ORS in enteric illness due to particular patho-
gens-producing cholera-like enterotoxins.
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